TURNOVER (x1000 SEK)
NET PROFIT (x1000 SEK)
EMPLOYEES
Calliditas Therapeutics AB
Closing information (x1000 SEK)
| Closing information | 2025/03 | 2023/12 (consolidated) | 2022/12 (consolidated) |
| Turnover |
1,958,890
|
1,206,888
|
802,879 |
| Financial expenses |
535,251
|
114,349
|
37,669 |
| Earnings before taxes |
-629,376
|
-457,017
|
-409,417 |
| EBITDA |
-131,600
|
-356,461
|
-409,030 |
| Total assets |
2,404,112
|
1,859,245
|
1,952,973 |
| Current assets |
1,181,015
|
1,275,152
|
1,412,204 |
| Current liabilities |
707,242
|
407,144
|
325,230 |
| Equity capital |
161,955
|
334,806
|
766,263 |
| - share capital |
2,398
|
2,383
|
2,383 |
| Employees (average) |
62
|
181
|
86 |
Financial ratios
| Fiscal year | 2025/03 | 2023/12 (consolidated) | 2022/12 (consolidated) |
| Solvency |
6.7%
|
18.0%
|
39.2% |
| Turnover per employee |
31,595
|
6,668
|
9,336 |
| Profit as a percentage of turnover |
-32.1%
|
-37.9%
|
-51.0% |
| Return on assets (ROA) |
-3.9%
|
-18.4%
|
-19.0% |
| Current ratio |
167.0%
|
313.2%
|
434.2% |
| Return on equity (ROE) |
-388.6%
|
-136.5%
|
-53.4% |
| Change turnover | |||
| Change turnover % |
50%
|
250% | |
| Chg. No. of employees | |||
| Chg. No. of employees % |
110%
|
54% |
Total value of public sale
| Fiscal year | 2025/03 | 2023/12 (consolidated) | 2022/12 (consolidated) |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.